Professor Benoit Arsenault
Disclosure details
Professor Arsenault is a consultant for Novartis, Eli Lilly and Silence Therapeutics and has received research contracts from Pfizer, Eli Lilly Ionis Pharmaceuticals and Silence Therapeutics.Department of Medicine, Faculty of Medicine, Université Laval, Québec (QC) Canada and Research Scientist, Québec Heart and Lung Institute, Québec (QC) Canada
Professor Arsenault joined the Department of Medicine of Université Laval in 2013. He is also a Research Scientist in the cardiology axis at the Québec Heart and Lung Institute.
Professor Arsenault’s team use genetic tools such as Mendelian randomization and family studies to investigate the causes and consequences of cardiometabolic diseases such as non-alcoholic fatty liver disease, dyslipidemia, type 2 diabetes and cardiovascular diseases. He also leads research programs funded by the Canadian Institutes of Health Research on the identification of therapeutic targets for cardiometabolic diseases and on the basic and genetic mechanisms through which PCSK9 and Lipoprotein(a) contribute to heart valve disorders such as calcific aortic valve stenosis.
Professor Arsenault holds a senior scholar award from the Fonds de recherche du Québec: Santé (FRQS) and his research is also funded by the Foundation of the Québec Heart and Lung Institute. He is also the Co-President of the Québec Society of Lipidology, Nutrition and Metabolism (SQLNM). He has authored or co-authored more than 190 peer-reviewed manuscripts.
Areas of special interest
- Genetic epidemiology
- Lp(a)-lowering therapies
- Calcific aortic valve stenosis
- Atherosclerotic cardiovascular diseases
